Get to know our clinical trials
Estudio de fase 3, aleatorizado, doble ciego, comparativo con un placebo, para investigar el efecto de tirzepatida sobre la reducción de la morbimortalidad en adultos con obesidad
THE MAIN OBJECTIVE OF YOUR PARTICIPATION IN THIS STUDY IS NOT TO PROVIDE TREATMENT FOR YOUR DISEASE, BUT TO HELP FIND AN ANSWER TO THE FOLLOWING SCIENTIFIC QUESTION: WHETHER TIRZEPATIDE CAN PROVIDE BENEFIT TO PATIENTS WITH OBESITY AND INCREASED RISK OF CARDIOVASCULAR EVENTS.
Technical Summary
- ESTUDIO DE FASE 3, ALEATORIZADO, DOBLE CIEGO, COMPARATIVO CON UN PLACEBO, PARA INVESTIGAR EL EFECTO DE TIRZEPATIDA SOBRE LA REDUCCIÓN DE LA MORBIMORTALIDAD EN ADULTOS CON OBESIDAD
- Code EudraCT: 2022-500817-14-00
- Protocol number: I8F-MC-GPIJ
- Promoter: Lilly
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.